SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description

   
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back


National Association For Continuing Education


Course Directors
Gregg Sherman, MD
Chief Medical Officer, NACE
Plantation, FL

Deborah Paschal, CRNP
Clinical Nurse Practitioner
Cardiothoracic Surgery Division
Penn-Presbyterian Medical Center
Philadelphia, PA

Medical Writer
Josh Kilbridge
Kilbride Associates Healthcare Communications
San Francisco, CA

Faculty
Franck Rahaghi, MD, MHS, FCCP
Director, Pulmonary Hypertension Clinic
Director, Pulmonary Education and Rehabilitation
Cleveland Clinic Florida
Weston, FL

Fernando Martinez, MD, MS
Executive Vice Chair of Medicine
Weill Cornell Medical Center
New York, NY

Ganesh Raghu, MD
Professor of Medicine and Laboratory Medicine
Director, Center for Interstitial Lung Diseases
Co-Director, Scleroderma Lung Clinic
University of Washington School of Medicine
Seattle, WA

Title
: Idiopathic Pulmonary Fibrosis: Making Sense of Diagnostic and Therapeutic Options in Primary Care
Activity/Course #:
: NCME316
Cost:
: Free
Release/Start Date:
: Jan 23 2017
Expiration Date:
: Jan 22 2018
Topics:
: Pulmonology
Target Audience:
: Primary Care Providers
Format:
: Monograph
Estimated Time To Complete CME Activity:
: 1.0 Hour
Credit(s):
: 1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s) which includes 0.25 pharmacology hour(s)
Hardware/Software Requirements:
(Chrome not supported at this time)
This monograph will provide information about Idiopathic Pulmonary Fibrosis (IPF). IPF is a rare, but deadly lung disorder that can be difficult to recognize and diagnose. A type of interstitial lung disease (ILD), IPF is characterized by insidious onset, nonspecific symptoms of cough and dyspnea, and a progressive decline in lung function caused by fibrosis of the lung parenchyma. The prognosis of IPF is poor. The estimated median survival is 3.8 years from diagnosis, and the only intervention so far shown to improve survival is lung transplantation.1,2 Furthermore, the diagnosis of IPF is often missed or delayed. The gradual onset and nonspecific symptoms of IPF may be inadequately investigated or confused with more common diseases, leaving patients untreated or inappropriately treated. Diagnostic delays may also limit the types of treatments available to patients (such as lung transplantation) and can lead to increased healthcare costs, reduced patient quality of life, and shortened survival.

Learning Objective(s):

After completing this program participants should be able to:

  1. Implement an appropriate strategy for diagnosing a patient with IPF
  2. Discuss and contrast the available pharmacotherapeutic options for patients with IPF
  3. Describe the non-pharmacotherapeutic options for IPF patients
  4. Establish the clear role for the primary care clinician in diagnosing and managing disease in IPF patients

How To Obtain Your CME Certificate

  1. Register for the course at www.naceonline.com.
  2. View the content.
  3. Complete and submit the post-test and evaluation.
  4. A minimum passing score of 80% must be earned on the post-test in order to complete the CME activity.
  5. Print your CME certificate.
Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education (which includes 0.25 pharmacology hours).
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosures are provided below.

Franck Rahaghi, MD, MHS, FCCP, Faculty, serves as Consultant/Lecturer – Baxter, Grifols, CSL Behring; Lecturer – Forest, Boehringer Ingelheim; Consultant – Intermune; Research – Gilead, Boehringer.

Fernando Martinez, MD, Faculty, serves as on Advisory Board – Amgen, Boehringer Ingelheim, ConCert, Genentech, GSK, Novartix, Pearl, ProterrixBio, Theravance; Steering Committee – AstraZeneca, Bayer, Gilead, GSK, Merck (formerly Afferent), Veracyte
Speaking – AstraZeneca, Boehringer Ingelehim, Novartis; Teleconference – Adept, Mereo, Unity; CME – Academic CME, Integritas, Miller Medical, Platform IQ, Potomac, Prime, WebMD, Up To Date; DSMB – Stromedix/Biogen, GSK.

Gregg Sherman, MD, Co-Course Director, has no relationships to disclose.

Deborah Paschal, CRNP, Co-Course Director, has no relationships to disclose.

Josh Kilbridge, Medical Writer, has no relationships to disclose.

Harvey C. Parker, Ph.D., Activity Planning Committee, has no relationships to disclose.

Michelle Frisch, MPH, Activity Planning Committee, has no relationships to disclose.

Alan Goodstat, LCSW, Activity Planning Committee, has no relationships to disclose.

Cheryl C. Kay, Activity Planning Committee, has no relationships to disclose.
Commercial Support
This activity is supported by is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.